Adrian Krainer wins RNA Society’s Lifetime Achievement Award March 8, 2019 Professor Adrian Krainer was awarded the RNA Society’s Lifetime Achievement Award for his life-saving research.
National Academy of Inventors Fellow, Adrian Krainer December 11, 2018 Professor Adrian Krainer has been named a NAI 2018 Fellow for his work on the first FDA-approved treatment for spinal muscular atrophy.
Big bold dreamers December 10, 2018 Dreamers drive discoveries. CSHL honors its many scientists making big impacts in their respective fields.
Breakthrough Prize laureates meet at CSHL December 6, 2018 Breakthrough Prize winner Adrian Krainer & C. Frank Bennett reunite for the first time since their award ceremony at CSHL to discuss further project.
Breakthrough Prize to CSHL professor for SMA research October 17, 2018 Professor Adrian Krainer has received a Breakthrough Prize in Life Sciences for his work on the first FDA-approved treatment of SMA.
Predicting how splicing errors impact disease risk August 30, 2018 New research helps correlate genetic mutations with errors in RNA splicing that can cause serious illness
CSHL helps ring opening bell at Nasdaq August 21, 2018 CSHL Professor Adrian Krainer and his team join the Spinal Muscular Atrophy (SMA) Foundation in ringing the Nasdaq opening bell
Therapeutic RNA corrects splicing defect that causes familial dysautonomia April 30, 2018 A team provides proof of concept for an RNA drug correcting an error in RNA splicing that causes familial dysautonomia (FD)
New method identifies splicing biomarkers for liver cancer March 2, 2018 Researchers have developed a method for identifying splicing-based biomarkers for liver cancer
Welcome to the real world of science, I’ll be your guide February 5, 2018 Jackie Novatt was determined to show the people on her campus tours how science really works—and landed her dream job in the process.
FDA approval of life-saving SMA drug is hailed by its researcher-inventor at CSHL December 24, 2016 Nusinersen (Spinraza) will be used to treat young children with a severe and potentially fatal illness called spinal muscular atrophy (SMA).
One experiment: A drug for SMA visibly repairs defective cells December 1, 2016 Professor Adrian Krainer develops a treatment for spinal muscular atrophy, the leading genetic cause of infant death.
“Sink or swim” October 15, 2016 This episode of Base Pairs follows Professor Adrian Krainer and his experience as the first CSHL fellow.
Candidate drug for spinal muscular atrophy, with roots in CSHL research, passes major hurdle August 4, 2016 Biotechnology firms Biogen and Ionis Pharmaceuticals cut short a phase-3 clinical trial for the investigational drug nusinersen as it met endpoint.
Adrian Krainer of Cold Spring Harbor Laboratory elected to American Academy of Arts and Sciences April 20, 2016 Adrian Krainer was elected to the American Academy of Arts and Sciences.
